A carregar...
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T‐Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease
On November 15, 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended the extension of indication for blinatumomab to include the treatment of adults with minimal residual disease (MRD) positive B‐cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab was authorized to...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7160312/ https://ncbi.nlm.nih.gov/pubmed/32297447 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0559 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|